Skip to main content

MoneyWorks4Me

Bajaj Healthcare informs about press release

04 Oct 2025 Evaluate
Bajaj Healthcare has informed that the company has received recommendation from Subject Expert Committee (SEC) (Neurology & Psychiatry) of Central Drugs Standard Control Organisation (CDSCO) to conduct Phase III clinical trials for Suvorexant Tablets 5mg, 10mg, 50mg, 15mg & 20mg. The press release in this regard, being issued by the Company is submitted.

The above information is a part of company’s filings submitted to BSE. 
Peers
Company Name CMP
Sun Pharma. Inds. 1761.30
Dr. Reddys Labs. 1339.95
Cipla 1364.30
Lupin 1986.20
Zydus Lifesciences 1185.80
View more..